Work

A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps2691

Authors: Adam Sharp, Anja Williams, Sarah Patricia Blagden, Elizabeth Ruth Plummer, Daniel Hochhauser, Matthew Krebs, Simon Pacey, T.R. Jeffry Evans, Sarah Whelan, Srinand Nandakumar, Seema Rogers, Katherine L. Jameson, Frank G. Basile, Johann S. De Bono, Hendrik-Tobias Arkenau

Institutions: Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Sarah Cannon Research Institute, University of Oxford, Newcastle University, University College London, The Christie NHS Foundation Trust, Beatson West of Scotland Cancer Centre, University of Glasgow, Nurix (United States), Royal Marsden Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286295205

Cites:

Cited by: 13

Related to: 10